67 citations
,
December 2015 in “Journal of the National Comprehensive Cancer Network” The guidelines aim to find treatable prostate cancer early while avoiding unnecessary tests and treatments.
August 2010 in “Oncology Times” Provenge extends prostate cancer survival by about 4 months.
1 citations
,
October 2006 in “Oncology times” Finasteride improves prostate cancer detection in PSA test.
147 citations
,
June 2011 in “New England journal of medicine/The New England journal of medicine” 5α-reductase inhibitors may prevent prostate cancer but could also raise the risk of more severe cancers.
December 2012 in “Canadian Urological Association Journal” 5-alpha reductase inhibitors help treat prostate issues in aging men, but their role in cancer prevention is debated.
1 citations
,
January 2020 in “Skin appendage disorders” Finasteride is safe for hair loss treatment and doesn't increase high-grade prostate cancer risk.
3 citations
,
March 2005 in “The Journal of urology/The journal of urology” Dutasteride may help shrink prostate cancer tumors.
February 2007 in “Lancet Oncology” Using a single PSA level to decide on a prostate biopsy is not effective; a more personalized approach considering various factors is recommended.
12 citations
,
June 2013 in “The Prostate” Dutasteride and finasteride affect different cell types differently.
9 citations
,
October 2013 in “PLOS ONE” Dutasteride works better than finasteride for preventing and treating prostate cancer.
8 citations
,
December 2016 in “Revista Medica De Chile” Finasteride can cause sexual dysfunction, sperm changes, and affect bone density and metabolism.
1 citations
,
July 2024 in “The International Journal of Medical Science and Health Research” 5α-reductase inhibitors may help with prostate cancer but could increase the risk of severe tumors, so careful use is advised.
75 citations
,
January 2014 in “Korean Journal of Urology” 5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.
52 citations
,
February 2006 in “Current pharmaceutical design” 5α-reductase inhibitors and alpha-1 adrenergic antagonists together effectively treat benign prostatic hyperplasia, with long-term benefits.
35 citations
,
April 2013 in “Sexual medicine reviews” 5-alpha reductase inhibitors slightly increase the risk of sexual and mood side effects, and breast growth in men.
23 citations
,
August 2005 in “Expert opinion on pharmacotherapy” New treatments for low male hormones improved sexual function and mood but had unclear risks, especially for older men.
15 citations
,
July 2016 in “Urologic Clinics of North America” Finasteride and dutasteride are effective for long-term treatment of enlarged prostates but have sexual side effects and a risk of high-grade prostate cancer.
4 citations
,
July 2021 in “Journal of Dermatological Treatment” Finasteride helps hair growth but may cause sexual side effects and depression.
1 citations
,
August 2015 in “Current Sexual Health Reports” 5α-reductase inhibitors can cause serious and possibly lasting sexual and psychological side effects.
108 citations
,
February 2008 in “The Journal of urology/The journal of urology” Inhibiting 5α-reductase can help reduce prostate cancer risk and improve treatment.
1 citations
,
April 2019 in “Clinical Breast Cancer” Medicines for enlarged prostate may raise the risk of breast growth and tenderness but not breast cancer.
April 2012 in “The Journal of Urology” More prostate biopsies increase the chance of finding cancers that may not need treatment.
April 2017 in “Austin Journal of Cancer and Clinical Research” 5α-reductase inhibitors like Finasteride and Dutasteride may help manage prostate cancer by blocking testosterone conversion.
218 citations
,
December 2011 in “Advances in Urology” The document concludes that the 5 alpha-reductase enzymes are important in steroid metabolism and related to various human diseases, with inhibitors used to treat conditions like male pattern baldness and prostate issues.
63 citations
,
December 2013 in “PLoS ONE” Finasteride may reduce prostate cancer spread by lowering certain enzyme levels.
39 citations
,
January 2012 in “Indian Dermatology Online Journal” Finasteride may cause sexual side effects like erectile dysfunction, but they are reversible and affect less than 2% of men.
37 citations
,
May 2007 in “International Journal of Pharmaceutics” PPCM microspheres allow controlled finasteride release over 24 hours.
35 citations
,
May 2020 in “Frontiers in Pharmacology” Different drugs for prostate-related urinary symptoms work but have various side effects, and treatment should be tailored to the individual.
35 citations
,
June 2018 in “Urology” The review suggests younger men taking 1 mg finasteride report more side effects, including sexual, skin, metabolic, and psychological issues.
35 citations
,
January 2012 in “The Journal of Sexual Medicine” Androgen Deprivation Therapy for prostate cancer often reduces sexual function but intermittent therapy may be more tolerable.